A phase 3, randomized, double-blind study to evaluate the safety and efficacy of GF-9350-boosted Atazanavir versus Ritonavir-boosted Atazanavir each administered with Emtricitabine/Tenofovir disoproxil fumarate in HIV-1 infected, antiretroviral treatment-naïve adults

This is a multicenter phase III, randomized, double-blind, active-controlled study to evaluate the safety and efficacy of a regimen containing GS-9350-boosted atazanavir (ATV/GS-9350) versus ritonavir-boosted atazanavir (ATV/r) each administered with emtricitabine/tenofovir disoproxil fumarate (Truvada®, FTC/TDF) in HIV-1 infected, antiretroviral treatment-naïve adult subjects.